Effect of a single intraoperative high-dose ATG-fresenius on delayed graft function in donation after cardiac-death donor renal allograft recipients: A randomized study

Experimental and Clinical Transplantation

Volumn 11, Issue 2, 2013, Pages 134-141

  van den Hoogen, Martijn W F ^a   Kho, Marcia M L ^b   Abrahams, Alferso C ^c   van Zuilen, Arjan D ^c   Sanders, Jan Stephan ^d   van Dijk, Marja ^d   Hilbrands, Luuk B ^a   Weimar, Willem ^b   Hoitsma, Andries J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anti T lymphocyte immunoglobulin; Delayed graft function; Donation after cardiac death

Indexed keywords

ATG FRESENIUS; IMMUNOGLOBULIN ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; T LYMPHOCYTE IMMUNOGLOBULIN ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART DEATH; HEMOLYSIS; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; KIDNEY ALLOGRAFT; MAINTENANCE THERAPY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; ORGAN DONOR; PEROPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

ADULT; AGED; ANTILYMPHOCYTE SERUM; DEATH; DELAYED GRAFT FUNCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; T-LYMPHOCYTES; TACROLIMUS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84876084507     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2012.0220     Document Type: Article

References (17)

1. Keizer KM, de Fijter JW, Haase-Kromwijk BJ, Weimar W. Non-heart-beating donor kidneys in the Netherlands: allocation and outcome of transplantation. Transplantation. 2005;79(9):1195-1199.
2. Weber M, Dindo D, Demartines N, Ambühl PM, Clavien PA. Kidney transplantation from donors without a heartbeat. N Engl J Med. 2002;347(4):248-255.
3. Sola R, Alarcón A, Jiménez C, Osuna A. The influence of delayed graft function. Nephrol Dial Transplant. 2004;19(suppl 3):iii32-iii37.
4. Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009;24(3):1039-1047.
5. Brook NR, White SA, Waller JR, Veitch PS, Nicholson ML. Non-heart beating donor kidneys with delayed graft function have superior graft survival compared with conventional heart-beating donor kidneys that develop delayed graft function. Am J Transplant. 2003;3(5):614-618.
6. Rabb H, Daniels F, O'Donnell M, et al. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol Renal Physiol. 2000;279(3):F525-F531.
7. Fang L, Fehse B, Engel M, Zander A, Kröger N. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation. 2005;79(3):369-371.
8. Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation. 2006;82(11):1387-1395.
9. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int. 1996;50(4):1089-1100.
10. Kyllönen LE, Eklund BH, Pesonen EJ, Salmela KT. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation. 2007;84(1):75-82.
11. Kaden J, May G, Völp A, Wesslau C. Improved long-term survival after intra-operative single high-dose ATG-Fresenius induction in renal transplantation: a single centre experience. Ann Transplant. 2009;14(3):7-17.
12. Kaden J, May G, Müller P, et al. Intraoperative high-dose anti-T-lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival. Transplant Proc. 1995;27(1):1060-1061.
13. Yussim A, Shapira Z. Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation--a prospective, randomized study. Transpl Int. 2000;13(suppl 1):S293-S294.
14. Ulrich F, Niedzwiecki S, Pascher A, et al. Long-term outcome of ATG vs. Basiliximab induction. Eur J Clin Invest. 2011;41(9):971-978.
15. Martins L, Fonseca I, Almeida M, et al. Immunosuppression with antithymocyte globulin in renal transplantation: better long-term graft survival. Transplant Proc. 2005;37(6):2755-2758.
16. Remberger M, Svahn BM, Hentschke P, Löfgren C, Ringdén O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24(8):823-830.
17. Wang D, Chen JH, Wu WZ, et al. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients. Transplant Proc. 2007;39(1):69-72.